Developer docs
API playgroundTry for free, no card

Search company profiles

Occam Dx

Full company profile

uuid002hr2p

Namestring
Occam Dx
Legal namestring
Occam Dx
Websiteurl
occamdx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Occam Dx is a Dutch medical technology company developing a point-of-care infectious disease diagnostic platform built on a patented nano-electronic biosensor. The system is designed to detect and count individual virus or bacterium particles directly from bodily fluid samples without the amplification step required by conventional microbiology, positioning the company as introducing what it describes as '22nd century diagnostics.' The platform comprises three integrated components: a portable SPOC instrument deployed at point-of-care sites, single-use cartridges each containing a predetermined pathogen panel for one patient, and cloud-based software that transmits test data to remote microbiologists for real-time diagnostic analysis.

The technology is rooted in proprietary bio-functionalization and signal processing capable of probing individual antibody/antigen interactions at very small analyte sizes. Occam Dx targets point-of-care healthcare settings including GP offices, emergency rooms, and ICUs where it seeks to replace expensive, slow, and labor-intensive conventional microbiology workflows with a faster, more accessible, and cost-effective procedure. The company is currently seeking Series A capital and is actively recruiting US-based partners for medical pilots, including contract research organizations for technology validation, microbiologists for use case development, and healthcare corporates for implementation. Headquartered at the University of Twente campus in Enschede, Netherlands, Occam Dx operates with a leadership team that includes a CEO and CTO alongside academic advisors from the University of Twente.

Short descriptiontext

Occam Dx is a Netherlands-based medical technology company that has developed a portable point-of-care diagnostic platform using a patented nano-electronic biosensor to detect and count individual pathogens, targeting GP offices, emergency rooms, and ICUs with cartridge-based testing and cloud-connected microbiologist analysis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEnschede, Netherlands
HQ citystring
Enschede
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, nanotechnology biosensors, infectious disease testing, lab-on-a-chip devices, pathogen detection systems
Industry4 codes
PRIMARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAOAJ
Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Point-of-care infectious disease diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1SPOC Instrument subscription
TypeSubscription Recurring
Description

The SPOC instrument is provided under a subscription model, with one device per point-of-care location. The instrument is portable and designed for use at GP offices, emergency rooms, and other clinical settings.

occamdx.com
2Single-use cartridge sales
TypeHardware Sales
Description

Single-use disposable cartridges sold on a per-patient basis, each containing a predetermined pathogen panel. This creates recurring consumable revenue alongside the instrument subscription.

occamdx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Pricing details2 tiers
1SPOC Instrument subscription
ModelSubscriptionBilling cadenceMulti-year contract
Notes

One SPOC instrument per point-of-care location under subscription model

occamdx.com
2Cartridge (single-use)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

One cartridge per patient with predetermined pathogen panel

occamdx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Occam Dx offers a point-of-care diagnostic platform comprising the portable SPOC Instrument, single-use pathogen-panel cartridges, and a cloud-based software platform. The system uses a proprietary nano-electronic biosensor to detect and count individual virus and bacterium particles in bodily fluids without amplification, transmitting data via the cloud to remote microbiologists for real-time diagnosis in GP offices, emergency rooms, and ICUs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Detect single virus or bacterium particles
+2 more records
Product overview1 text field

Occam Dx offers a diagnostic platform consisting of three integrated components: a portable SPOC Instrument for point-of-care testing, single-use Cartridges with predetermined pathogen panels, and cloud-based Software connecting caregivers, patients, and microbiologists. The system uses a proprietary nano-electronic biosensor to detect and count individual pathogens in bodily fluids, enabling rapid, reliable diagnosis at GP offices, emergency rooms, and ICUs with real-time microbiologist analysis.

Product and service3 records
1SPOC Instrument
2Cartridge
3Software Platform
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

European-headquartered diagnostics incumbent offering a broad infectious-disease menu including POCT molecular and immunoassay solutions. Comparable as an established European diagnostics player with overlapping ID testing portfolios.

TypeDirect peer
Description

QIAstat-Dx is a cartridge-based syndromic POCT system used in ER/ICU for respiratory, GI, and meningitis panels. Closely matches Occam's cartridge + instrument architecture and syndromic panel positioning.

TypeEmerging player
Description

T2 Magnetic Resonance diagnostics platform for direct-from-sample detection without amplification. Conceptually comparable to Occam's amplification-free single-particle detection approach, though focused on sepsis and Candida.

TypeBroad incumbent
Description

Broad molecular diagnostics incumbent with Panther Fusion for high-throughput and Novodiag for cartridge-based near-patient testing. Comparable as a large incumbent offering cartridge-based molecular panels.

TypeDirect peer
Description

Market-leading molecular POCT platform (GeneXpert) deployed in GP, ER, and ICU settings for infectious disease testing. Directly comparable to Occam Dx's SPOC in target customer, point-of-care use case, and infectious-disease menu focus.

TypeDirect peer
Description

FilmArray syndromic panels are the gold standard for multiplex infectious-disease POCT in hospitals and emergency settings. Directly comparable as a cartridge-based, predetermined-panel, point-of-care platform.

TypeEmerging player
Description

UK-based developer of Q-POC, a portable molecular POCT device targeting infectious disease at point of care. Highly comparable as an emerging nano/molecular POCT competitor with similar form factor and global health ambitions.

8Abbott (ID NOW / Panbio)
TypeBroad incumbent
Description

Abbott's ID NOW molecular POCT and rapid antigen tests dominate near-patient infectious disease testing globally. Comparable as a broad incumbent offering POCT solutions across the same point-of-care customer segments.

TypeEmerging player
Description

Developer of the binx io molecular POCT platform, primarily focused on CT/NG STI testing at point of care. Comparable as an emerging cartridge-based rapid molecular POC player in infectious disease.

10Mesa Biotech (Now part of Mesa Labs)
TypeDirect peer
Description

Developer of the Accula molecular POCT system for infectious disease (flu, RSV, Strep A, SARS-CoV-2). Comparable as a small cartridge-based POCT targeting CLIA-waived and near-patient settings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Occam Dx

Point-of-care infectious disease diagnosticsoccamdx.com

Occam Dx is a Netherlands-based medical technology company that has developed a portable point-of-care diagnostic platform using a patented nano-electronic biosensor to detect and count individual pathogens, targeting GP offices, emergency rooms, and ICUs with cartridge-based testing and cloud-connected microbiologist analysis.

What Occam Dx does

Occam Dx is a Dutch medical technology company developing a point-of-care infectious disease diagnostic platform built on a patented nano-electronic biosensor. The system is designed to detect and count individual virus or bacterium particles directly from bodily fluid samples without the amplification step required by conventional microbiology, positioning the company as introducing what it describes as '22nd century diagnostics.' The platform comprises three integrated components: a portable SPOC instrument deployed at point-of-care sites, single-use cartridges each containing a predetermined pathogen panel for one patient, and cloud-based software that transmits test data to remote microbiologists for real-time diagnostic analysis.

The technology is rooted in proprietary bio-functionalization and signal processing capable of probing individual antibody/antigen interactions at very small analyte sizes. Occam Dx targets point-of-care healthcare settings including GP offices, emergency rooms, and ICUs where it seeks to replace expensive, slow, and labor-intensive conventional microbiology workflows with a faster, more accessible, and cost-effective procedure. The company is currently seeking Series A capital and is actively recruiting US-based partners for medical pilots, including contract research organizations for technology validation, microbiologists for use case development, and healthcare corporates for implementation. Headquartered at the University of Twente campus in Enschede, Netherlands, Occam Dx operates with a leadership team that includes a CEO and CTO alongside academic advisors from the University of Twente.

Occam Dx firmographics

Firmographics
Name
Occam Dx
Legal name
Occam Dx
Website
https://occamdx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Occam Dx is a Netherlands-based medical technology company that has developed a portable point-of-care diagnostic platform using a patented nano-electronic biosensor to detect and count individual pathogens, targeting GP offices, emergency rooms, and ICUs with cartridge-based testing and cloud-connected microbiologist analysis.
Ownership category
akta.pro rank

Occam Dx industry classification

Industry
Product category
Point-of-care infectious disease diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAOAJ
Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

Keywords

  • Point-of-care diagnostics
  • Nanotechnology biosensors
  • Infectious disease testing
  • Lab-on-a-chip devices
  • Pathogen detection systems

Where Occam Dx is headquartered

Location

Headquarters

HQ city
Enschede
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Occam Dx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. SPOC Instrument subscription: The SPOC instrument is provided under a subscription model, with one device per point-of-care location. The instrument is portable and designed for use at GP offices, emergency rooms, and other clinical settings.
  2. Single-use cartridge sales: Single-use disposable cartridges sold on a per-patient basis, each containing a predetermined pathogen panel. This creates recurring consumable revenue alongside the instrument subscription.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractSPOC Instrument subscription
Unit PricingPay-as-you-goCartridge (single-use)

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Occam Dx product offering

Product offering

Core offering

Occam Dx offers a point-of-care diagnostic platform comprising the portable SPOC Instrument, single-use pathogen-panel cartridges, and a cloud-based software platform. The system uses a proprietary nano-electronic biosensor to detect and count individual virus and bacterium particles in bodily fluids without amplification, transmitting data via the cloud to remote microbiologists for real-time diagnosis in GP offices, emergency rooms, and ICUs.

Product overview

Occam Dx offers a diagnostic platform consisting of three integrated components: a portable SPOC Instrument for point-of-care testing, single-use Cartridges with predetermined pathogen panels, and cloud-based Software connecting caregivers, patients, and microbiologists. The system uses a proprietary nano-electronic biosensor to detect and count individual pathogens in bodily fluids, enabling rapid, reliable diagnosis at GP offices, emergency rooms, and ICUs with real-time microbiologist analysis.

Differentiator

Problem solved

Functional benefit

Products and services

  • SPOC Instrument
  • Cartridge
  • Software Platform

Quantifiable outcome

  • Detect single virus or bacterium particles
  • +2 more outcomes

Companies that use Occam Dx

Customer profile

Segments4 records

Ideal customer profiles2 records

Occam Dx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Occam Dx partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Occam Dx competitors and assessment

Company assessment

Broad incumbents

  • DiaSorin (Liaison/MDx): European-headquartered diagnostics incumbent offering a broad infectious-disease menu including POCT molecular and immunoassay solutions. Comparable as an established European diagnostics player with overlapping ID testing portfolios.
  • Hologic (Panther Fusion / Novodiag): Broad molecular diagnostics incumbent with Panther Fusion for high-throughput and Novodiag for cartridge-based near-patient testing. Comparable as a large incumbent offering cartridge-based molecular panels.
  • Abbott (ID NOW / Panbio): Abbott's ID NOW molecular POCT and rapid antigen tests dominate near-patient infectious disease testing globally. Comparable as a broad incumbent offering POCT solutions across the same point-of-care customer segments.

Direct peers

  • Qiagen (QIAstat-Dx): QIAstat-Dx is a cartridge-based syndromic POCT system used in ER/ICU for respiratory, GI, and meningitis panels. Closely matches Occam's cartridge + instrument architecture and syndromic panel positioning.
  • Cepheid (Danaher): Market-leading molecular POCT platform (GeneXpert) deployed in GP, ER, and ICU settings for infectious disease testing. Directly comparable to Occam Dx's SPOC in target customer, point-of-care use case, and infectious-disease menu focus.
  • bioMérieux (BioFire): FilmArray syndromic panels are the gold standard for multiplex infectious-disease POCT in hospitals and emergency settings. Directly comparable as a cartridge-based, predetermined-panel, point-of-care platform.
  • Mesa Biotech (Now part of Mesa Labs): Developer of the Accula molecular POCT system for infectious disease (flu, RSV, Strep A, SARS-CoV-2). Comparable as a small cartridge-based POCT targeting CLIA-waived and near-patient settings.

Emerging players

  • T2 Biosystems: T2 Magnetic Resonance diagnostics platform for direct-from-sample detection without amplification. Conceptually comparable to Occam's amplification-free single-particle detection approach, though focused on sepsis and Candida.
  • QuantuMDx: UK-based developer of Q-POC, a portable molecular POCT device targeting infectious disease at point of care. Highly comparable as an emerging nano/molecular POCT competitor with similar form factor and global health ambitions.
  • binx health: Developer of the binx io molecular POCT platform, primarily focused on CT/NG STI testing at point of care. Comparable as an emerging cartridge-based rapid molecular POC player in infectious disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

Occam Dx social profiles

Digital presence

Occam Dx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Occam Dx leadership team

Management profile

Number of profiles

Profiles8 records

Occam Dx funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Occam Dx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Occam Dx

What does Occam Dx do?

Occam Dx offers a point-of-care diagnostic platform comprising the portable SPOC Instrument, single-use pathogen-panel cartridges, and a cloud-based software platform. The system uses a proprietary nano-electronic biosensor to detect and count individual virus and bacterium particles in bodily fluids without amplification, transmitting data via the cloud to remote microbiologists for real-time diagnosis in GP offices, emergency rooms, and ICUs.

Is Occam Dx a public or private company?

Occam Dx is a private company. It is classified as unknown and is currently operating.

When was Occam Dx founded?

Occam Dx was founded in 2019. It employs 1 to 10 people.

Where is Occam Dx based?

Occam Dx is headquartered in Enschede, Netherlands, in the Europe region.

How does Occam Dx make money?

Two revenue lines are on record. SPOC Instrument subscription is the primary driver. The others are single-use cartridge sales.

Who are Occam Dx's main competitors?

Broad incumbents on record are DiaSorin (Liaison/MDx), Hologic (Panther Fusion / Novodiag) and Abbott (ID NOW / Panbio). Direct peers are Qiagen (QIAstat-Dx), Cepheid (Danaher), bioMérieux (BioFire) and Mesa Biotech (Now part of Mesa Labs). Emerging players are T2 Biosystems, QuantuMDx and binx health.

Does Occam Dx have an API?

No public API is recorded for Occam Dx.

What industry is Occam Dx in?

Occam Dx's product category is Point-of-care infectious disease diagnostics. Its primary akta.pro industry code is HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis), with a secondary code of HLAHAOAJ, Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales